Cryo-Save N.V. has acquired Salveo Biotechnology SA
Cryo-Save N.V. (Cryo-Save), the largest family stem cell bank in Europe, has acquired Salveo Biotechnology SA, the cord banking activities of Salveo Holding SA (Salveo), for an undisclosed consideration.
Cryo-Save is the leading international stem cell storage brand. It offers collection, analysis, processing and cryogenic preservation of stem cells obtained from the umbilical cord and from umbilical cord blood that can be used in medical therapies later in a child’s lifetime.
Salveo Biotechnology SA is the umbilical cord blood and umbilical cord tissue cryopreservation division of Salveo Holding SA, a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine.
Salveo Holding SA is a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine. Founded in 2011 and made up of experts in regenerative medicine, the group is also present in Italy, Spain, Portugal and Ukraine and has developed a dynamic and professional commercial network.
Salveo was selected to partner with Cryo-Save, acquiring all assets related to the distribution and commercial activities of Salveo's umbilical cord blood and umbilical cord tissue cryopreservation business. Frédéric Amar, CEO of Salveo, has also joined the board of Cryo-Save as non-Executive Director.
Oaklins' team in the Netherlands identified potential partners, initiated contact and led talks on potential cooperation with a number of parties and advised the buyer in this transaction.
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreClinical Partners has raised new debt facilities
Clinical Partners Ltd. has successfully restructured and upsized its debt facilities to better reflect the scale of the business. The company increased its original US$9.4 million facility, comprising a US$3.4 million term loan and a US$6 million revolving credit facility (RCF), to a US$27 million RCF.
Learn more